Trade Vir Biotechnology VIR

Magbenta
 Bumili

VirBiotechnology live chart

5m 15m 30m 1h 4h 1d 1w

Mga Pangunahing Kaalaman sa Instrumento

Weekly Search
Weekly
Daily
Petsa Isarado Pagbabago Change (%) Buksan High Low

VirBiotechnology news

Mga pinakabagong balita

Ipakita nang marami
Ava Grace 2025 Aug 12, 03:20

US CPI Data July: A Risky Economic Outlook Unveiled

Australia inflation rate ticks up to 3.6% in April
Tommy Yap 2025 Aug 12, 02:23

Morning Note: RBA Rate Cut; US CPI Awaited; Ethereum Rallies on Inflows

Morning Note Cryptocurrencies Monetary Policy
Ghko B 2025 Aug 11, 16:00

Stock Market Today: Dow Fluctuates as Trump Extends China Tariff Deadline

Stocks
Sophia Claire 2025 Aug 11, 14:20

Indian Rupee Under Pressure: RBI Intervenes Amid Trade Tensions

Noah Lee 2025 Aug 11, 10:04

Israeli Minister Doubts Netanyahu's Ability to Achieve 'Decisive Victory' in Gaza

2025 Aug 11, 09:20

Trump-Putin Talks Spark Rally in Ukraine, Russia-Linked Assets

2025 Aug 11, 09:20

Europe Urges US to Ramp Up Russia Sanctions Before Trump-Putin Meeting

Sophia Claire 2025 Aug 11, 01:20

US Treasury Chief: Tariffs, Trade Imbalance, and the Fed's Future

Info

Spread

0.03

Spread (%)

0.7059 %

Leverage

1:10

Interes sa Magdamagang Pagbili

-0.0597 %

Interes sa Magdamagang Pagtinda

-0.0292 %

Currency

USD

Trading Hours

Oras ng Pagsasara

Martes

13:31 - 19:59

Lunes

13:31-19:59

Miyerkules

13:31-19:59

Huwebes

13:31-19:59

Biyernes

13:31-19:59

Analys och statistik

Buksan

---

Nakaraang Pagsara

---

52 Linggo Mataas/Mababa

--- – ---

Market Cap

594560512

Natitirang Pagbabahagi

138916000

Petsa ng Mga Kita (Susunod)

0000-00-00

Pambayad si dividend

Araw ng Pag-alis ng Karapatan sa Dividend

Inaasahang Taunang Rate ng Dividend

0

Inaasahang Taunang Dividend Yield

0

EPS

-4.01

Alamin ang Higit Pa Tungkol sa Instrumentong ito

Vir Biotechnology Vir Biotechnology Inc
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors.The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). It has grant agreements with Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.

Mga kaugnay na instrumento

Asset
Magbenta
Bumili
Change (%)

Mag-trade Ngayon

Mag-trade Ngayon

Mag-trade Ngayon

Mag-trade Ngayon
view_all_instruments

latest_education_articles

Ipakita nang marami
Trustpilot